Article

Iodine may alleviate retinitis pigmentosa swelling

Researchers from Massachusetts Eye and Ear, Harvard Medical School, and Boston University School of Medicine have found that the extent of retinal swelling due to cystoid macular edema (CME) was inversely related to dietary iodine intake in patients with retinitis pigmentosa (RP).

 

Boston-Researchers from Massachusetts Eye and Ear, Harvard Medical School, and Boston University School of Medicine have found that the extent of retinal swelling due to cystoid macular edema (CME) was inversely related to dietary iodine intake in patients with retinitis pigmentosa (RP).

The finding raises the possibility that an iodine supplement could help limit or reduce central foveal swelling in RP patients with CME, according to the researchers. Their results can be found online in the July issue of JAMA Ophthalmology.

Previous research performed showed an inverse association between the presence of CME and reported iodine supplementation in patients with RP. This finding, along with physiology research by others, pointed to iodine as being worth investigating further.

In this new experiment, the researchers performed a cross-sectional observational study of 212 non-smoking patients 18 to 69 years of age who were referred to Massachusetts Eye and Ear for RP with visual acuity of no worse than 20/200 in at least one eye. They then used optical coherence tomography to measure central foveal swelling due to CME in the patients. Total dietary intake of iodine was estimated from multiple spot urine samples collected at the patients’ home.

 

The investigators found that the magnitude of central foveal swelling due to CME was inversely related to urinary iodine concentration when emphasizing data with more reproducible urinary idodine concentrations (p < .001). Patients with the lowest urinary iodine levels tended to have retinas with the most swelling, according to the researchers.

“Additional study is required to determine whether an iodine supplement can limit or reduce the extent of CME in patients with RP,” said Michael A. Sandberg, PhD, lead author of the study and senior scientist in the Berman-Gund Laboratory for the Study of Retinal Degenerations at Massachusetts Eye and Ear, and associate professor of ophthalmology, Harvard Medical School.

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.